SureNano Science Launches IND-Enabling Program for Obesity and Diabetes Drug GEP-44, Targeting a $200 Billion Market

SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) has taken a significant step toward clinical development by initiating a Good Laboratory Practice (GLP) toxicology and pharmacology program for its lead drug candidate GEP-44. The program is designed to align with U.S. Food and Drug Administration (FDA) requirements and support an Investigational New Drug (IND) application, a prerequisite for first-in-human clinical trials.

GEP-44 is a multi-receptor peptide targeting obesity and type 2 diabetes, positioning the company within the booming GLP-1 therapeutic market. Preclinical results suggest GEP-44 is competitive with established drugs such as Ozempic, Mounjaro, and Wegovy. The studies will assess safety, dosing thresholds, and pharmacological effects across multiple species, with the goal of supporting a Phase I clinical trial in Australia, subject to regulatory submission and outcomes.

The global GLP-1 receptor agonist market is experiencing explosive growth, with projections ranging from $100 billion to J.P. Morgan estimates of the broader incretin market reaching $200 billion by 2030. Approximately 25 million patients in the United States alone are expected to use GLP-1 therapies by 2030. SureNano aims to capture a share of this market as an agile entrant, having secured licensing rights to GEP-44 from Syracuse University.

In addition to its obesity and diabetes pipeline, SureNano is exploring the acquisition or licensing of Ibogaine-related intellectual property for potential mental health and addiction treatments. This move underscores the company's transition toward a pharmaceutical-focused model following its acquisition of GlucaPharm.

SureNano's progress is closely watched by investors. For the latest news and updates relating to SURNF, visit the company's newsroom at https://ibn.fm/SURNF.